

Clinical trials of Fluoxetine

TrialResults-center www.trialresultscenter.org

1 obesity and overweight

Trial	Treatments	Patients	Trials design and methods
Fluoxetine vs placebo			
Breum , 1995 n=20/20 follow-up:	Fluoxetine, 60 mgfor 52 wk versus Placebo	aaaa	
Connolly , 1995 n=15/15 follow-up:	fluoxetine 60 mg daily versus placebo	obese elderly patients over 60 years of age with Type 2 diabetes	double-blind
Darga , 1991 n=23/22 follow-up: 52 weeks	fluoxetine versus placebo	obese subjects	
Goldstein , 1994 n=182/184 follow-up: 52-week	Fluoxetine, 60 mgfor 52 wk versus Placebo	obese outpatients	double-blind
Gray , 1992 n=24/24 follow-up: 24 weeks	Fluoxetine, 60 mg for 6 mo versus Placebo	obese, type 2 non-insulin dependent diabetics being treated with insulin	double blind
Marcus , 1990 n=23/22 follow-up:	Fluoxetine, 60 mgfor 52 wk versus Placebo	-	
Mendoza Espejo , 1995 n=0/30 follow-up:	Fluoxetine, 180 mgfor 6 mo versus Placebo	-	
Michelson 50wk , 1999 n=102/102 follow-up:	Fluoxetine, 20 mgfor 50 wk versus Placebo	-	
OKane , 1994 n=10/10 follow-up:	-	-	

More details and results :

- All mechanism for obesity and overweight in all type of patients at <http://www.trialresultscenter.org/go-Q265>

References

Breum, 1995:

Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. *Metabolism* 1995 Dec;44:1570-6 [[8786726](#)]

Connolly, 1995:

Connolly VM, Gallagher A, Kesson CM A study of fluoxetine in obese elderly patients with type 2 diabetes. *Diabet Med* 1995 May;12:416-8 [[7648804](#)]

Darga, 1991:

Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP Fluoxetine's effect on weight loss in obese subjects. *Am J Clin Nutr* 1991 Aug;54:321-5 [[1858696](#)]

Goldstein, 1994:

Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR Fluoxetine: a randomized clinical trial in the treatment of obesity. *Int J Obes Relat Metab Disord* 1994 Mar;18:129-35 [[8186809](#)]

Gray, 1992:

Gray DS, Fujioka K, Devine W, Bray GA Fluoxetine treatment of the obese diabetic. *Int J Obes Relat Metab Disord* 1992 Mar;16:193-8 [[1317828](#)]

Marcus, 1990:

Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. *Am J Psychiatry* 1990 Jul;147:876-81 [[2192563](#)]

Mendoza Espejo, 1995:

Mendoza Espejo R, Diaz Perez de Madrid J, Buitrago F [Effectiveness of serotonergic agonists in the treatment of obese patients] *Aten Primaria* 1995 Oct 15;16:364-6 [[7488690](#)]

Michelson 50wk, 1999:

Michelson D, Amsterdam JD, Kim Y, Sundell K.nten Changes in weight during a one-year trial with fluoxetine [Abstract] 152nd Annual Meeting of

OKane, 1994:

O'Kane M, Wiles PG, Wales JK Fluoxetine in the treatment of obese type 2 diabetic patients. *Diabet Med* 1994 Jan-Feb;11:105-10 [[8181239](#)]